No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 99
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
230 (estimated)
Sponsor
Amgen · Industry
Who this trial is looking for
This trial is looking for adults who are overweight or obese and want to try a new treatment. Participants will use an autoinjector to give themselves the medication at home.
Are You a Good Fit for This Trial?
Rules you outType 1 diabetesType 2 diabetesPancreatitisCancer
You may be able to join if
I have a BMI of 30 or higher, or I have a BMI of 27 to 30 with a health condition.
I have tried to lose weight through diet and exercise before.
I use contraception if I am female.
I am willing to follow the trial procedures.
You may not be able to join if
I have had a significant weight change of more than 5 kg in the last 90 days.
I have had surgery for obesity before or I am planning one.
I have a history of cancer in the last 5 years.
I have Type 1 or Type 2 diabetes.
I have chronic pancreatitis or had acute pancreatitis in the last 180 days.
I have a family or personal history of medullary thyroid cancer.
I have participated in a Maridebart Cafraglutide trial before.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Body mass index (BMI) ≥ 30 kilograms per meter square (kg/m\^2), or BMI ≥ 27 to \< 30 kg/m\^2 with one of the following:
* hypertension: treated, or with systolic blood pressure ≥ 130 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 80 mmHg
* dyslipidemia: trea…
Inclusion Criteria:
* Body mass index (BMI) ≥ 30 kilograms per meter square (kg/m\^2), or BMI ≥ 27 to \< 30 kg/m\^2 with one of the following:
* hypertension: treated, or with systolic blood pressure ≥ 130 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 80 mmHg
* dyslipidemia: treated or previously diagnosed high cholesterol, high triglycerides, or low HDL cholesterol.
* history of obstructive sleep apnea
* history of cardiovascular disease
* history of fatty liver disease (including metabolic dysfunction-associated steatotic liver disease \[MASLD\] or metabolic dysfunction-associated steatohepatitis \[MASH\])
* At least 1 unsuccessful attempt at weight loss by diet and exercise.
* Contraception for females.
* Willingness to follow trial procedures for the duration of the trial.
Exclusion Criteria:
* Obesity induced by other endocrinologic disorders.
* Change in body weight \> 5 kg within last 90 days.
* Previous or planned surgical, endoscopic, or device-based treatment for obesity.
* History of malignancy within the past 5 years.
* Type 1 or Type 2 diabetes mellitus.
* History of chronic pancreatitis or history of acute pancreatitis within last 180 days.
* Family or personal history of medullary thyroid cancer.
* Previous participation in a Maridebart Cafraglutide trial.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.